S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
An All-In-One Guide for Trading Metals (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
An All-In-One Guide for Trading Metals (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
An All-In-One Guide for Trading Metals (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
An All-In-One Guide for Trading Metals (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
An All-In-One Guide for Trading Metals (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
An All-In-One Guide for Trading Metals (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
An All-In-One Guide for Trading Metals (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
An All-In-One Guide for Trading Metals (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
An All-In-One Guide for Trading Metals (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
An All-In-One Guide for Trading Metals (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
An All-In-One Guide for Trading Metals (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
An All-In-One Guide for Trading Metals (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
NYSE:HAE

Haemonetics - HAE Stock Forecast, Price & News

$83.72
+0.20 (+0.24%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$82.83
$84.09
50-Day Range
$74.03
$86.14
52-Week Range
$43.50
$86.58
Volume
210,293 shs
Average Volume
473,705 shs
Market Capitalization
$4.24 billion
P/E Ratio
50.43
Dividend Yield
N/A
Price Target
$96.17

Haemonetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
14.9% Upside
$96.17 Price Target
Short Interest
Healthy
2.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.69mentions of Haemonetics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.57 M Sold Last Quarter
Proj. Earnings Growth
4.90%
From $2.86 to $3.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

55th out of 1,022 stocks

Surgical & Medical Instruments Industry

4th out of 101 stocks

HAE stock logo

About Haemonetics (NYSE:HAE) Stock

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Stock News Headlines

Haemonetics (NYSE:HAE) Hits New 1-Year High at $86.50
Haemonetics (NYSE:HAE) Hits New 52-Week High at $86.50
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
Here's Why Haemonetics (HAE) is a Strong Growth Stock
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Company Calendar

Last Earnings
11/09/2021
Today
12/08/2022
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
2,821
Year Founded
1971

Price Target and Rating

Average Stock Price Forecast
$96.17
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+14.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$43.38 million
Pretax Margin
10.45%

Debt

Sales & Book Value

Annual Sales
$993.20 million
Cash Flow
$4.55 per share
Book Value
$14.66 per share

Miscellaneous

Free Float
49,773,000
Market Cap
$4.24 billion
Optionable
Optionable
Beta
0.37

Social Links


Key Executives

  • Mr. Christopher A. SimonMr. Christopher A. Simon (Age 58)
    CEO, Pres & Director
    Comp: $1.88M
  • Mr. Josep Lluis Llorens (Age 59)
    Exec. VP of Global Manufacturing & Supply Chain
    Comp: $718.76k
  • Mr. Stewart W. StrongMr. Stewart W. Strong (Age 55)
    Pres of Global Hospital
    Comp: $918.03k
  • Mr. James C. D'Arecca CPA (Age 51)
    CFO, Exec. VP & Financial Officer
  • Ms. Farris Maryanne Maunsell (Age 47)
    VP, Chief Accounting Officer & Principal Accounting Officer
  • Ms. Anila  LingamneniMs. Anila Lingamneni (Age 54)
    Exec. VP & CTO
  • Ms. Olga Guyette
    Director of Investor Relations
  • Carla Burigatto
    VP of Communications
  • Mr. Francis Tan
    Sr. VP of Corp. Devel. & Planning
  • Ms. Laurie A. MillerMs. Laurie A. Miller
    Sr. VP & Chief HR Officer













HAE Stock - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2023?

7 brokerages have issued 12 month price targets for Haemonetics' stock. Their HAE share price forecasts range from $88.00 to $105.00. On average, they expect the company's stock price to reach $96.17 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2022?

Haemonetics' stock was trading at $53.04 at the beginning of the year. Since then, HAE stock has increased by 57.8% and is now trading at $83.72.
View the best growth stocks for 2022 here
.

Are investors shorting Haemonetics?

Haemonetics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,230,000 shares, a decrease of 26.3% from the October 31st total of 1,670,000 shares. Based on an average trading volume of 429,900 shares, the short-interest ratio is presently 2.9 days. Approximately 2.5% of the company's shares are sold short.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its earnings results on Tuesday, November, 9th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by $0.01. The medical instruments supplier earned $239.90 million during the quarter, compared to analyst estimates of $240.85 million. Haemonetics had a trailing twelve-month return on equity of 20.05% and a net margin of 7.94%. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 earnings per share.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2023 earnings guidance on Monday, November, 21st. The company provided earnings per share guidance of $2.70-$3.00 for the period, compared to the consensus EPS estimate of $2.79. The company issued revenue guidance of $1.11 billion-$1.14 billion, compared to the consensus revenue estimate of $1.09 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), APA (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.27%), Neuberger Berman Group LLC (7.69%), Fisher Asset Management LLC (2.43%), Royce & Associates LP (1.70%), LGT Capital Partners LTD. (1.50%) and Dimensional Fund Advisors LP (1.40%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $83.72.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $4.24 billion and generates $993.20 million in revenue each year. The medical instruments supplier earns $43.38 million in net income (profit) each year or $1.66 on an earnings per share basis.

How many employees does Haemonetics have?

The company employs 2,821 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 12/9/2022 by MarketBeat.com Staff